Spectrum Pharma (SPPI) Tops Q2 EPS by 4c

Spectrum Pharma (NASDAQ: SPPI) reported Q2 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32).

“The recently announced positive results from Cohort 2 are a meaningful development for patients with NSCLC HER2 exon 20 insertion mutations for which there is no approved therapy,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “We are in the process of requesting a pre-NDA meeting with the FDA and look forward to reviewing this data with the agency. In addition, the BLA for ROLONTIS is under active FDA review with a PDUFA date of October 24, 2020. We are in a strong capital position to fund our ongoing development and commercialization of our late stage assets.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• VivoPower posts $6.8M revenue and $0.6M profit in Q1 FY2027
• Definitive Healthcare names new CPO and AI head ahead of platform launch
• Uber Q3 profit, revenue beat estimates as gross bookings jump 20%